Cost-effectiveness of somatostatin analogues in the treatment of acromegaly

被引:9
作者
Orlewska, Ewa [1 ]
Stepien, Renata [1 ]
Orlewska, Katarzyna [2 ]
机构
[1] Jan Kochanowski Univ, Fac Med & Hlth Sci, Al 9 Wiekow Kielc 19, PL-25317 Kielce, Poland
[2] Med Univ Warsaw, Fac Med, Warsaw, Poland
关键词
Acromegaly; somatostatin analogues; cost-effectiveness; ECONOMIC-EVALUATION; LANREOTIDE AUTOGEL; UNITED-STATES; CARE; MANAGEMENT; COMPLICATIONS; PEGVISOMANT; THERAPIES; CONSENSUS; GERMANY;
D O I
10.1080/14737167.2018.1513330
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Somatostatin analogues (SSAs) are the largest contributor to the direct medical cost of acromegaly management worldwide. The aim of this review was to identify and report available evidence on the cost-effectiveness of SSAs in the treatment of acromegaly. Areas covered: A literature search on relevant papers published up to April 2018 was performed. A total of 22 eligible studies (10 full-text articles and 12 conference abstracts) conducted in 14 countries were included in the analysis. In majority of studies, modelling technique was the principal research method. Expert commentary: The results of cost-effectiveness analyses: 1) support published recommendations where SSAs are indicated as first-line medical treatment for patients with persistent disease after surgery or who are not eligible for surgery; 2) suggest that preoperative medical therapy with SSAs may be highly cost-effective in acromegalic patients with macroadenoma, in centres without optimal surgical results 3) indicate that in some countries pasireotide and pegvisomant appeared to be cost-effective or even dominant strategies in comparison to first-generation SSAs. The main limitation of economic evaluations was the lack of high-quality studies designed to directly compare various treatment strategies in acromegaly.
引用
收藏
页码:15 / 25
页数:11
相关论文
共 45 条
[1]   COST-EFFECTIVENESS OF SOMASTATIN ANALOGUES FOR THE TREATMENT OF ACROMEGALY IN COLOMBIA [J].
Alfonso, R. ;
Izquierdo, C. ;
Diaz-Sotelo, O. D. ;
Maestre, K. ;
Zarate, J. P. .
VALUE IN HEALTH, 2010, 13 (03) :A59-A59
[2]   CHARACTERISTICS OF LONG-ACTING SOMATOSTATIN (SSA) USE IN ACROMEGALY IN THE NETHERLANDS [J].
Bezemer, I. D. ;
Penning, F. J. A. ;
Brulais, S. ;
Verduyn, C. S. C. ;
Herings, R. M. C. .
VALUE IN HEALTH, 2012, 15 (07) :A506-A506
[3]   New medical therapies on the horizon: oral octreotide [J].
Biermasz, Nienke R. .
PITUITARY, 2017, 20 (01) :149-153
[4]  
Biermasz Nienke R, 2009, Expert Rev Pharmacoecon Outcomes Res, V9, P223, DOI 10.1586/erp.09.17
[5]   Acromegaly - a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports [J].
Bolanowski, Marek ;
Ruchala, Marek ;
Zgliczynski, Wojciech ;
Kos-Kudla, Beata ;
Baldys-Waligorska, Agata ;
Zielinski, Grzegorz ;
Bednarczuk, Tomasz ;
Hubalewska-Dydejczyk, Alicja ;
Kaminski, Grzegorz ;
Marek, Bogdan ;
Daroszewski, Jacek ;
Wasko, Ryszard ;
Lewinski, Andrzej .
ENDOKRYNOLOGIA POLSKA, 2014, 65 (04) :326-331
[6]   Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases [J].
Broder, M. S. ;
Neary, M. P. ;
Chang, E. ;
Cherepanov, D. ;
Katznelson, L. .
PITUITARY, 2014, 17 (04) :333-341
[7]   A COST-EFFECTIVENESS ANALYSIS OF PASIREOTIDE LONG-ACTING COMPARED TO CONTINUED USE OF A FIRST-LINE SOMATOSTATIN ANTAGONIST FOR THE TREATMENT OF ACROMEGALY IN SWEDEN [J].
Carlqvist, P. ;
Wilen-Koort, A. .
VALUE IN HEALTH, 2016, 19 (07) :A591-A591
[8]   Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly [J].
Chanson, P ;
Boerlin, V ;
Ajzenberg, C ;
Bachelot, Y ;
Benito, P ;
Bringer, J ;
Caron, P ;
Charbonnel, B ;
Cortet, C ;
Delemer, B ;
Escobar-Jiménez, F ;
Foubert, L ;
Gaztambide, S ;
Jockenhoevel, F ;
Kuhn, JM ;
Leclere, J ;
Lorcy, Y ;
Perlemuter, L ;
Prestele, H ;
Roger, P ;
Rohmer, V ;
Santen, R ;
Sassolas, G ;
Scherbaum, WA ;
Schopohl, J ;
Torres, E ;
Varela, C ;
Villamil, F ;
Webb, SM .
CLINICAL ENDOCRINOLOGY, 2000, 53 (05) :577-586
[9]   Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly [J].
Colao, Annamaria ;
Auriemma, Renata S. ;
Pivonello, Rosario ;
Kasuki, Leandro ;
Gadelha, Monica R. .
PITUITARY, 2016, 19 (03) :235-247
[10]   Cost-of-illness study in acromegalic patients in Italy [J].
Didoni, G ;
Grottoli, S ;
Gasco, V ;
Battistini, M ;
Ferone, D ;
Giusti, M ;
Ragazzoni, F ;
Ruffo, P ;
Ghigo, E ;
Minuto, F .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (11) :1034-1039